Sage Therapeutics

Press Releases

Press Releases

07-23-2014

SAGE Therapeutics Announces Closing of Initial Public Offering
Read the Press Release

07-22-2014

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
Read the Press Release

07-21-2014

SAGE Therapeutics Announces Full Exercise of Over-Allotment Option
Read the Press Release

07-17-2014

SAGE Therapeutics Announces Pricing of Initial Public Offering
Read the Press Release

06-10-2014

SAGE Therapeutics Appoints James M. Frates to the Company's Board of Directors
Read the Press Release

06-5-2014

SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference
Read the Press Release

05-5-2014

SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
Read the Press Release

05-1-2014

SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
Read the Press Release

04-1-2014

SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors
Read the Press Release

03-27-2014

SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
Read the Press Release

03-13-2014

SAGE Therapeutics Closes $38M Oversubscribed Series C Financing
Read the Press Release

02-5-2014

SAGE Therapeutics to Present at the 2014 Leerink Global Healthcare Conference
Read the Press Release

01-6-2014

SAGE Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Read the Press Release

12-19-2013

SAGE Therapeutics Announces Collaboration with Washington University to Develop Novel GABA Receptor Small Molecules
Read the Press Release

12-9-2013

SAGE Therapeutics Presents New Data Identifying Highly Selective, Oral Compounds and Novel Approach for the Treatment of Chronic Epilepsies
Read the Press Release

11-18-2013

SAGE's Novel Approach to Treatment of CNS Disorders to be Highlighted at Leading Industry and Scientific Conferences
Read the Press Release

11-12-2013

SAGE Presents New Mechanistic Insights On Novel Approach to NMDA Receptor Modulation
Read the Press Release

10-30-2013

SAGE's Discovery of Novel Allosteric Therapeutic Approach for a Broad Range of CNS Disorders Published in Journal of Neuroscience
Read the Press Release

10-16-2013

SAGE Therapeutics Secures $20M Series B Financing
Read the Press Release